Algert Global’s Standard BioTools LAB Stock Holding History

Algert Global’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25,117	Closed	-$44K	–	1397
2024 Q2	$44K	Buy	+25,117	New	+$61.4K	﹤0.01%	1445
2023 Q4	–	Sell	-26,090	Closed	-$76K	–	1195
2023 Q3	$76K	Hold	26,090	–	–	﹤0.01%	1047
2023 Q2	$50K	Buy	+26,090	New	+$51.5K	﹤0.01%	1057
2021 Q4	–	Sell	-50,015	Closed	-$330K	–	1045
2021 Q3	$330K	Sell	50,015 -40,345	-45%	-$265K	0.04%	723
2021 Q2	$557K	Buy	90,360 +69,770	+339%	+$373K	0.19%	174
2021 Q1	$93K	Buy	+20,590	New	+$113K	0.03%	415
2020 Q3	–	Sell	-37,050	Closed	-$149K	–	449
2020 Q2	$149K	Sell	37,050 -13,770	-27%	-$48K	0.05%	350
2020 Q1	$129K	Buy	+50,820	New	+$167K	0.05%	341
2019 Q1	–	Sell	-56,019	Closed	-$483K	–	354
2018 Q4	$483K	Buy	+56,019	New	+$436K	0.13%	227

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Algert Global's LAB Position: Q3 2024 in Review

Algert Global sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 25,117 shares — an estimated $44K sold.

Algert Global first reported a position in LAB in Q4 2018 and held it in 9 quarters. The position peaked at $557K in Q2 2021. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

Algert Global reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
Algert Global sold 25,117 Standard BioTools shares in Q3 2024, an estimated $44K.
Algert Global first reported a position in Standard BioTools in Q4 2018 and held it in 9 quarters.
Algert Global's Standard BioTools position peaked at $557K in Q2 2021.
141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on Algert Global's 13F filing for Q3 2024, filed 12 Nov 2024.